Pacira Pharmaceuticals Stock Total Asset
| PCRX Stock | USD 26.51 0.01 0.04% |
Pacira Pharmaceuticals fundamentals help investors to digest information that contributes to Pacira Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 1.6 B | 1.7 B | |
| Intangibles To Total Assets | 0.41 | 0.43 |
Pacira | Total Asset |
Pacira Pharmaceuticals Company Total Asset Analysis
Pacira Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Pacira Pharmaceuticals Total Asset | 1.57 B |
Most of Pacira Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pacira Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Pacira Pharmaceuticals is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as Total Asset. Since Pacira Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Pacira Total Asset Historical Pattern
Today, most investors in Pacira Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pacira Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pacira Pharmaceuticals total asset as a starting point in their analysis.
Pacira Pharmaceuticals Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Pacira Total Assets
Total Assets |
|
Based on the latest financial disclosure, Pacira Pharmaceuticals has a Total Asset of 1.57 B. This is 79.06% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 94.66% higher than that of the company.
Pacira Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pacira Pharmaceuticals by comparing valuation metrics of similar companies.Pacira Pharmaceuticals is currently under evaluation in total asset category among related companies.
Pacira Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Pacira Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pacira Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pacira Pharmaceuticals' value.| Shares | Rock Springs Capital Management Lp | 2023-12-31 | 1.1 M | Pacer Advisors, Inc. | 2023-12-31 | 1 M | Rice Hall James & Associates, Llc | 2023-12-31 | 1 M | Geode Capital Management, Llc | 2023-12-31 | 1 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 685.3 K | Schroder Investment Management Group | 2023-12-31 | 621.7 K | Hhg Plc | 2023-12-31 | 604 K | Gagnon Securities Llc | 2023-12-31 | 545.6 K | Northern Trust Corp | 2023-12-31 | 528.3 K | Blackrock Inc | 2023-12-31 | 8.1 M | Vanguard Group Inc | 2023-12-31 | 5.1 M |
Pacira Fundamentals
| Return On Equity | 0.051 | ||||
| Return On Asset | 0.0335 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 1.54 B | ||||
| Shares Outstanding | 46.52 M | ||||
| Shares Owned By Insiders | 1.26 % | ||||
| Shares Owned By Institutions | 98.74 % | ||||
| Number Of Shares Shorted | 3.45 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 1.85 X | ||||
| Revenue | 674.98 M | ||||
| Gross Profit | 393.23 M | ||||
| EBITDA | 162.9 M | ||||
| Net Income | 41.95 M | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 586.04 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 18.72 X | ||||
| Cash Flow From Operations | 154.65 M | ||||
| Short Ratio | 7.57 X | ||||
| Earnings Per Share | 0.89 X | ||||
| Price To Earnings To Growth | (3.83) X | ||||
| Target Price | 46.4 | ||||
| Number Of Employees | 711 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 1.23 B | ||||
| Total Asset | 1.57 B | ||||
| Retained Earnings | (106.8 M) | ||||
| Working Capital | 412.61 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
| Net Asset | 1.57 B |
About Pacira Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacira Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pacira Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Pacira Pharmaceuticals Piotroski F Score and Pacira Pharmaceuticals Altman Z Score analysis. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 0.89 | Revenue Per Share 14.603 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0335 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.